PPI Sequencing Study

AstraZeneca100 enrolled

Overview

The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Gastro-Oesophageal Reflux Disease

Interventions

EsomeprazoleDRUG

Physical examPROCEDURE

Pregnancy test if applicablePROCEDURE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Persisting symptoms of GORD despite previous treatment with a full dose proton pump inhibitor * Informed consent * Over 18 years of age Exclusion Criteria: * Current course of Proton Pump inhibitor treatment for more than 8 weeks prior to enrolment in the study; * More than 1 other course of PPI treatment in the previous 12 month; * Previous use of esomeprazole; * Presence of alarm symptoms.

Locations (14)

Research Site

Allerton, United Kingdom

Research Site

Ashford, United Kingdom

Research Site

Atherstone, United Kingdom

Outcomes

Primary Outcomes

The primary objective of this study is to assess the change in the frequency of heartburn from baseline value at entry to the end of the study, after 8-weeks treatment with esomeprazole 40mg compared to previous full dose treatment with a PPI daily

Secondary Outcomes

Change in frequency and severity of heartburn, epigastric pain and acid regurgitation after 4 and 8 weeks treatment from baseline value at study entry

Change in symptom control from baseline to 4 and 8 weeks using QOL questionnaires

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.